First full year under Indiana's ban reveals 146 abortions occurred in 2024
In this photo illustration, packages of Mifepristone tablets are displayed at a family planning clinic on April 13, 2023 in Rockville, Maryland. (Photo illustration by)
An Indiana Department of Health report released in April shows a total of 146 abortions occurred in 2024 – a 98% decrease from 2022. This is the first annual terminated pregnancy report in which the state's near-total abortion ban was in full effect.
Ninety-three of the abortions were performed due to lethal fetal anomaly; 40 were due to serious health risk or life of the mother and nine were due to rape or incest.
More than half were performed by using an abortion pill or intracardiac injections.The rest were surgical procedures.
In 2023, while the ban was partially in effect, there were a total of 4,579 abortions performed in Indiana. Before the ban was in effect in 2022, there were a total of 9,529 abortions.
Half of the women who obtained an abortion were between the ages of 25-34 while only two were under the age of 16. Nearly half of the women indicated they were married.
Under the state's ban, abortions can only be done in hospitals.
CONTACT US
Nine hospitals in Marion, Allen and St. Joseph counties carried out the abortions. There were 67 terminations reported at Riley Health Maternity Tower and 52 reported at Sidney & Lois Eskanazi Hospital. Both of these hospitals are located in Indianapolis.
Indiana law requires that health care providers who perform terminated pregnancies report to the IDOH. Providers must report within 30 days if the patient is 16 or older and within three days if younger than 16. Each of the reports should include demographic, medical and procedural information.
While 142 terminated pregnancies reports were submitted to the IDOH through the electronic reporting system, Indiana University Health submitted four incomplete reports via email that lacked demographic, medical and procedural details. The reports did include that they occurred at an IU Health facility in 2024 but did not report all the required information.
Two doctors from IU Health testified in March that they haven't submitted the reports since Dec. 23 — when a new federal rule on reproductive health care privacy went into effect.
In January, Indiana Gov. Mike Braun signed new executive orders on abortion records to ensure the laws are 'fully and faithfully executed,' including terminated pregnancy report submissions.
In February, the Indiana Department of Health settled with an anti-abortion group – backed by Indiana Attorney General Todd Rokita – to continue to release individual reports filed on abortion after opting to no longer release these reports due to patient privacy concerns in December 2023.
A judge, however, blocked that release.
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
a day ago
- New York Times
A Day With One Abortion Pill Prescriber
The young woman's voice trembled over the phone. Sitting in her car in Alabama, where abortion is almost totally banned, the 26-year-old mother of two was grappling with an unintended pregnancy. 'I'm like 'How in the world?'' she said, stifling a sob. 'I already have two children, and I cannot. I can't. I just can't go through with it.' She wanted an abortion, she said, but was afraid of getting caught and didn't know what to expect from the process. 'Growing up, I never really thought about actually doing something like this,' she said. On the other end of the line, at home on a quiet residential street in Delaware, Debra Lynch, a nurse practitioner who runs a service prescribing abortion pills, spoke calmly. 'It's completely valid to be scared,' she said from her desk in a home office filled with plants and shelves of medication. 'And that's why we want you to call us, even if you're calling just to say: 'I'm scared. I need to hear somebody tell me that what's going on right now is normal, and it's OK.'' During the 25-minute conversation, Ms. Lynch asked the woman about her health history and pregnancy and assessed that she was medically eligible for abortion medications that can be taken in the first 12 weeks of pregnancy: mifepristone, which blocks a hormone necessary for pregnancy development, and misoprostol, taken 24 to 48 hours later, which causes contractions so pregnancy tissue can be expelled. Want all of The Times? Subscribe.
Yahoo
2 days ago
- Yahoo
AG pushes back on federal abortion medication restrictions
BOSTON (SHNS) – Attorney General Andrea Campbell implored federal regulators Thursday to eliminate medication abortion restrictions on prescribers and pharmacies, arguing Massachusetts already has 'robust' guardrails in place to protect patient safety. Campbell, along with AGs from California, New York and New Jersey, want the U.S. Food and Drug Administration to eliminate its Risk Evaluation and Mitigation Strategy (REMS) program for mifepristone — or at least stop applying certain parts of it to the four petitioning states. The program outlines certification requirements for health care providers and pharmacies to dispense mifepristone, plus paperwork that patients must sign. About 65% of abortions in Massachusetts in 2023 were medication abortions, according to the 64-page citizen petition Campbell co-filed Thursday. The FDA says REMS programs are used for drugs with 'serious safety concerns to help ensure the benefits of the medication outweigh its risks.' Campbell's office contends the mifepristone requirements impose 'burdensome restrictions on access to medication abortion while not meaningfully improving patient safety, and that these restrictions severely impede patient access by reducing the number of prescribers and pharmacies authorized to dispense this FDA-approved medication.' 'The Mifepristone REMS Program also imposes an undue burden on pregnant patients experiencing miscarriage and early pregnancy loss who seek treatment at emergency departments,' the petition says. 'For instance, the administrative requirements imposed by the REMS can effectively discourage emergency departments from carrying mifepristone in their pharmacies.' Reduced access to mifepristone can particularly impact patients in rural and medically underserved areas, the petition added. The Democratic AGs teamed up in response to U.S. Health and Human Services Secretary Robert Kennedy recently instructing FDA Commissioner Martin Makary to pursue a 'complete review' of mifepristone and labeling requirements. The FDA is required to respond to their petition within 180 days by either approving, denying or dismissing it — or providing a 'tentative response' about why the agency is unable to reach a decision yet, according to federal regulations. In response to the Trump administration, Beacon Hill lawmakers are escalating their focus on shoring up protections for reproductive and transgender care. A Sen. Cindy Friedman bill (S 2522) that's gaining traction would tighten the 2022 abortion shield law, including by requiring hospitals to provide emergency abortion care and allowing provider practices, rather than specific prescriber names, to appear on medication abortion labels. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Gizmodo
4 days ago
- Gizmodo
Four Democrat-Led States Ask FDA to Lift Restrictions on Abortion Pill
The attorneys general of four Democrat-led states—New York, New Jersey, Massachusetts, and California—petitioned the Food and Drug Administration on Thursday, June 5, asking the agency to lift what they view as unnecessary restrictions on the abortion pill mifepristone. The petition aims to force the FDA to acknowledge robust clinical evidence and decades of mifepristone use that support the drug's safety and efficacy. The move comes just one month after Health and Human Services Secretary Robert F. Kennedy Jr. told Congress that he ordered a safety review of the abortion pill. An FDA spokesperson confirmed plans for the review in a statement to CBS News on Tuesday, June 3. According to the FDA, mifepristone, approved by the regulator in 2000, is a drug that blocks the hormone progesterone, which is necessary for pregnancy to continue. It is most commonly used in combination with the drug misoprostol to terminate a pregnancy within 10 weeks of gestation. An analysis of 2023 data by the Guttmacher Institute found that medication abortions account for more than half (63%) of all abortions in the U.S. But in the years since the Supreme Court overturned Roe v. Wade, 17 states have banned this medication, and an additional 10 states have placed restrictions on it, according to the Washington Post. 'The medication is a lifeline for millions of women who need access to time-sensitive, critical healthcare—especially low-income women and those who live in rural and underserved areas,' California attorney general Rob Bonta told the Los Angeles Times. The petition specifically asks the FDA to lift the mifepristone Risk Evaluation and Mitigation Strategy (REMS) Program. This additional regulatory framework is designed to 'help ensure the benefits of the medication outweigh its risks,' according to the FDA. REMS has been applied to 325 medications since its inception and currently applies to 71 drugs. REMS places multiple restrictions on mifepristone use, including that prescribers be put on national and local abortion provider lists; patients give written statements that they intend to end their pregnancies; and pharmacies keep records of mifepristone prescribers and users. The attorneys general argue that these rules 'impose unnecessary and burdensome hurdles on patients, prescribers, pharmacists, and the healthcare system.' They also point out that mifepristone has been marketed in the U.S. for decades and has been safely used by more than 7.5 million American women. 'Moreover, no new evidence raising safety concerns has emerged in the last two decades,' they state. These states are not alone in their pursuit of expanded mifepristone access. Seventeen other Democratic-led or -leaning states, plus Washington D.C., are suing the FDA in Spokane, Washington, to loosen restrictions on the drug, Reuters reported in February. What's more, leading medical organizations have called on the FDA to remove REMS restrictions on mifepristone for years. If the FDA declines to remove REMS, Thursday's petition asks the agency to 'exercise its discretion not to enforce' some or all of the restrictions in New York, New Jersey, Massachusetts, and California, as these states already place 'rigorous restrictions' around the practice of medicine.
